Alnylam Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Frederic Tremblay

Mark K Schlegel

James D McIninch

Adam Castoreno

Charalambos Kaittanis

Gregory Hinkle

Stuart Milstein

Jesper Gromada

Aris I Baras

Xiping Cheng

Frederick E Dewey

Noura S Abul-Husn

Yurong Xin

Omri Gottesman

Alexander Li

Leila Noetzli

Alan R Shuldiner

Lucas D BonDurant

Alan Shuldiner

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a PNPLA3 gene and to methods of preventing and treating an PNPLA3-associated disorder, e.g., Nonalcoholic Fatty Liver Disease (NAFLD).

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B 13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.

17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.

17&#x3b2;-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the apolipoprotein C3 gene (APOC3). The invention also relates to methods of using such RNAi agents to inhibit expression of an APOC3 gene and to methods of preventing and treating an APOC3-associated disorder, e.g., hypertriglyceridemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, polycystic ovary syndrome, kidney disease, obesity, type 2 diabetes mellitus (insulin resistance), hypertension, artherosclerosis and pancreatitis.

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Growing community of inventors

Boston, MA, United States of America

Frederic Tremblay